加载中
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
收盘时
US$3.04
+US$0.19 · +6.67%
盘后
US$3.00
−US$0.04 · -1.32%
10月12日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
日内区间
当前US$3.04
52周区间
当前US$3.04
盘中时间采用ET。市场数据可能有所延迟。
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
日内区间
当前US$3.04
52周区间
当前US$3.04
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2.18万 USD | — | — | 23.33万 USD | 63.8万 USD |
| 销货成本 | 4231 USD | — | — | — | — |
| 毛利 | 1.76万 USD | — | — | 23.33万 USD | 63.8万 USD |
| 研究与开发 | 208.66万 USD | 49.27万 USD | 95.48万 USD | 94.28万 USD | 144.77万 USD |
| 销售、一般及管理费用 | 683.97万 USD | 259.86万 USD | 291.6万 USD | 272.29万 USD | 309.74万 USD |
| 营业费用 | 892.63万 USD | 309.13万 USD | 387.08万 USD | 366.57万 USD | 454.51万 USD |
| 利息收入 | — | 5557 USD | 482 USD | 617 USD | 132 USD |
| 利息支出 | 6.6万 USD | 24.84万 USD | 21.87万 USD | 74.09万 USD | 11.4万 USD |
| 营业利润 | −890.87万 USD | −309.13万 USD | −387.08万 USD | −343.24万 USD | −390.71万 USD |
| 净利润 | −864.49万 USD | −243.96万 USD | −478.37万 USD | −495.76万 USD | −437.94万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年8月7日 | 1:75 | — | — |
已生效 2026年8月7日
1:75
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
